$TAK · TAKEDA PHARMACEUTICAL CO LTD
Takeda filed its 6-K earnings report for H1 FY2026 (six months ended September 30, 2026). Revenue rose 8.4% AER to JPY 2,407.0B but fell 1.0% on a CER basis. Operating profit jumped 60.4% AER to JPY 406.7B, while net profit attributable to owners surged 171.8% to JPY 305.6B. Full-year management guidance on a constant-exchange-rate basis was revised down: Core Revenue to low-single-digit decline, Core Operating Profit to mid-single-digit decline, and Core EPS to low-teens decline.
- H1 FY2026 revenue: JPY 2,407.0B (+8.4% AER, -1.0% CER); operating profit JPY 406.7B (+60.4% AER, +45.0% CER)
- Net profit attributable to owners: JPY 305.6B (+171.8% YoY); basic EPS JPY 192.53 vs JPY 71.57 in H1 FY2025
- Core Operating Profit: JPY 710.6B (+11.2%); Core EPS JPY 308 vs JPY 279 in prior-year period
- Full-year FY2026 management guidance (CER): Core Revenue low-single-digit % decline, Core Operating Profit mid-single-digit % decline, Core EPS low-teens % decline
- Interim dividend raised to JPY 102/share (from JPY 100); full-year projection JPY 204/share
Markets closed — no regular-session reaction yet; extended-hours move not captured here.
The stark gap between 171.6% reported profit growth and deteriorating constant-currency fundamentals — with CER guidance cut across all metrics — signals that Takeda's underlying business is contracting despite yen-driven headline gains.
Takeda's results highlight the divergence between reported and constant-currency performance that plagues Japanese pharma — strong headline growth driven by yen weakness masks organic declines, a dynamic also facing peers like Astellas and Daiichi Sankyo.
CER-based management guidance cut across all core metrics signals underlying business erosion masked by favorable FX. Revenue declined 1.0% on a constant-currency basis despite 8.4% AER growth, and full-year CER Core EPS is guided to low-teens decline.